Aurobindo Pharma expects 25 products approvals in FY16 for US market
Approvals expect to drive 50 per cent growth in its injectables business in the next financial year
BS B2B Bureau B2B Connect | Hyderabad
New products are expected to help Aurobindo Pharma to grow its injectables business at 50 per cent in the next financial year. Aurobindo’s injectables business - currently comprising antibiotics and some antianxiety drugs - has been growing at a rapid pace and currently stood at $50 million for the nine-month period ending December 2014.
Meanwhile, the company also indicated that it would try to get out of the commodity type products across the portfolios, going forward. “In the next three to five years, I think, instead of looking at each business and looking at what is missing, overall we would like to see that the portfolio itself is moving out of commodity and becoming more and more differentiated is what we are focusing across the globe,” said N Govindarajan, Aurobindo Pharma's managing director, during a recent conference call with the analysts.
Also Read
FOR COMPLETE REPORT READ: Aurobindo foresees high growth in injectables biz
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Feb 17 2015 | 2:04 PM IST